These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 21788472)
1. CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections. Prichard MN; Kern ER; Hartline CB; Lanier ER; Quenelle DC Antimicrob Agents Chemother; 2011 Oct; 55(10):4728-34. PubMed ID: 21788472 [TBL] [Abstract][Full Text] [Related]
2. Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation. Venard V; Dauendorffer JN; Carret AS; Corsaro D; Edert D; Bordigoni P; Le Faou A Pathol Biol (Paris); 2001 Sep; 49(7):553-8. PubMed ID: 11642018 [TBL] [Abstract][Full Text] [Related]
3. Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome. Ziyaeyan M; Alborzi A; Japoni A; Kadivar M; Davarpanah MA; Pourabbas B; Abassian A Int J Dermatol; 2007 Dec; 46(12):1263-6. PubMed ID: 18173520 [TBL] [Abstract][Full Text] [Related]
5. Phenotypic testing of patient herpes simplex virus type 1 and 2 isolates for acyclovir resistance by a novel method based on real-time cell analysis. Caliaro O; Barbani MT; Klenja S; Morfin F; Frobert E; Gorgievski M; Steinlin-Schopfer J; Suter-Riniker F J Clin Virol; 2020 Apr; 125():104303. PubMed ID: 32163870 [TBL] [Abstract][Full Text] [Related]
6. Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner. Huang WY; Su YH; Yao HW; Ling P; Tung YY; Chen SH; Wang X; Chen SH J Gen Virol; 2010 Mar; 91(Pt 3):591-8. PubMed ID: 19906941 [TBL] [Abstract][Full Text] [Related]
7. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312 [TBL] [Abstract][Full Text] [Related]
8. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Neyts J; Andrei G; De Clercq E Antimicrob Agents Chemother; 1998 Feb; 42(2):216-22. PubMed ID: 9527762 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. Quenelle DC; Lampert B; Collins DJ; Rice TL; Painter GR; Kern ER J Infect Dis; 2010 Nov; 202(10):1492-9. PubMed ID: 20923374 [TBL] [Abstract][Full Text] [Related]
10. Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2. Sauerbrei A; Bohn K; Heim A; Hofmann J; Weissbrich B; Schnitzler P; Hoffmann D; Zell R; Jahn G; Wutzler P; Hamprecht K Antivir Ther; 2011; 16(8):1297-308. PubMed ID: 22155911 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antiherpetic effects of (1R,2R)-1-(5'-methylful-3'-yl)propane-1,2,3-triol. Sasaki K; Hayashi K; Matsuya Y; Sugimoto K; Lee JB; Kurosaki F; Hayashi T J Nat Med; 2016 Apr; 70(2):217-24. PubMed ID: 26763002 [TBL] [Abstract][Full Text] [Related]
12. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice. Afouna MI; Fincher TK; Zaghloul AA; Reddy IK Int J Pharm; 2003 Mar; 253(1-2):159-68. PubMed ID: 12593946 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child. Bryant P; Sasadeusz J; Carapetis J; Waters K; Curtis N Pediatr Infect Dis J; 2001 Nov; 20(11):1083-6. PubMed ID: 11734717 [TBL] [Abstract][Full Text] [Related]
15. 2-[4,5-Difluoro-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2. Strand M; Islam K; Edlund K; Oberg CT; Allard A; Bergström T; Mei YF; Elofsson M; Wadell G Antimicrob Agents Chemother; 2012 Nov; 56(11):5735-43. PubMed ID: 22908173 [TBL] [Abstract][Full Text] [Related]
16. Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain. Saijo M; Suzutani T; De Clercq E; Niikura M; Maeda A; Morikawa S; Kurane I Antiviral Res; 2002 Dec; 56(3):253-62. PubMed ID: 12406508 [TBL] [Abstract][Full Text] [Related]
17. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo. Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995 [TBL] [Abstract][Full Text] [Related]
18. [In vitro acyclovir and cidofovir susceptibilities of human herpesvirus type 1 clinical isolates]. Cieśluk B; Dzieciatkowski T; Majewska A; Łuczak M Med Dosw Mikrobiol; 2008; 60(2):163-8. PubMed ID: 18819452 [TBL] [Abstract][Full Text] [Related]
19. Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient. Andrei G; Fiten P; Goubau P; van Landuyt H; Gordts B; Selleslag D; De Clercq E; Opdenakker G; Snoeck R Transpl Infect Dis; 2007 Jun; 9(2):126-31. PubMed ID: 17461998 [TBL] [Abstract][Full Text] [Related]